Bempedoic acid for the treatment of dyslipidemia
Cardiovascular disease (CVD) is the leading cause of death worldwide and one key factor associated with the increased CVD risk is dyslipidemia. Statin therapy remains the first-line treatment to manage dyslipidemia, yet many patients do not achieve optimal low-density lipoprotein-cholesterol (LDL-C)...
Main Authors: | Joel C Marrs, Sarah L Anderson |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2020-08-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/bempedoic-acid-for-the-treatment-of-dyslipidemia |
Similar Items
-
Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
by: Agarwala A, et al.
Published: (2021-05-01) -
Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials
by: Xiang Zhao, et al.
Published: (2020-12-01) -
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis
by: Xing Wang, et al.
Published: (2020-08-01) -
Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS)
by: Margus Viigimaa, et al.
Published: (2014-01-01) -
KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid
by: Alegret, M., et al.
Published: (2022)